Awakn Life Sciences (TSE:AWKN) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Awakn Life Sciences has announced a binding letter of intent for its acquisition by Graft Polymer, a UK-based biotechnology company, marking a significant milestone for both companies. Each Awakn shareholder will receive 46.67 Graft shares for each common share, representing a 110.54% premium. This acquisition aims to enhance shareholder value and expand their reach in addressing mental health and addiction disorders.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.